Drug Administration Schedule

• 

  Subject Areas on Research

  • "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. 
  • 1 + 1 not equal to 2. 
  • 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 5-day methotrexate for women with metastatic gestational trophoblastic disease. 
  • A 102-center prospective study of seizure in association with bupropion. 
  • A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation. 
  • A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial. 
  • A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. 
  • A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 
  • A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. 
  • A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. 
  • A childlike presentation? 
  • A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. 
  • A comparison of the effects of caffeine following abstinence and normal caffeine use. 
  • A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. 
  • A double-blind, placebo-controlled trial of four fixed rate infusion regimens of phenylephrine for hemodynamic support during spinal anesthesia for cesarean delivery. 
  • A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. 
  • A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. 
  • A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. 
  • A multi-center, dose-escalation study of human type I pancreatic elastase (PRT-201) administered after arteriovenous fistula creation. 
  • A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. 
  • A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. 
  • A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections. 
  • A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. 
  • A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. 
  • A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer. 
  • A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. 
  • A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. 
  • A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. 
  • A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. 
  • A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. 
  • A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. 
  • A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. 
  • A phase I clinical and pharmacokinetic trial of hepsulfam. 
  • A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. 
  • A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. 
  • A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. 
  • A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. 
  • A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors. 
  • A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. 
  • A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. 
  • A phase I/II study of the protease inhibitor indinavir in children with HIV infection. 
  • A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study. 
  • A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study. 
  • A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. 
  • A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. 
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. 
  • A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. 
  • A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study. 
  • A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. 
  • A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study. 
  • A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. 
  • A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. 
  • A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. 
  • A pilot study to determine the feasibility of continuous cefazolin infusion. 
  • A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. 
  • A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200 ng/mL. 
  • A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. 
  • A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. 
  • A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. 
  • A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. 
  • A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. 
  • A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. 
  • A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. 
  • A randomized trial of transcutaneous electric acupoint stimulation as adjunctive treatment for opioid detoxification. 
  • A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. 
  • A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. 
  • A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. 
  • A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. 
  • A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. 
  • A randomized, open-label study of the safety and tolerability of fospropofol for patients requiring intubation and mechanical ventilation in the intensive care unit. 
  • A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). 
  • A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. 
  • A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. 
  • A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. 
  • A systematic review of antibiotic use and infection in breast reconstruction: what is the evidence? 
  • A systematic review of persistence and compliance with bisphosphonates for osteoporosis. 
  • A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. 
  • A trial of outpatient chemotherapy for recurrent head and neck tumors. 
  • AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. 
  • Abciximab readministration: results of the ReoPro Readministration Registry. 
  • Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. 
  • Acupuncture and related techniques for postoperative pain: a systematic review of randomized controlled trials. 
  • Acute administration of unacylated ghrelin has no effect on Basal or stimulated insulin secretion in healthy humans. 
  • Acute and chronic nicotinic interactions with dopamine systems and working memory performance. 
  • Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. 
  • Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. 
  • Adipogenic and lipolytic effects of chronic glucocorticoid exposure. 
  • Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. 
  • Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. 
  • Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. 
  • Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. 
  • Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. 
  • Adverse drug events caused by serious medication administration errors. 
  • Afterload reduction in chronic aortic regurgitation: it sure seems like a good idea. 
  • Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women. 
  • Age-related differences in neurosteroid potentiation of muscimol-stimulated 36Cl(-) flux following chronic ethanol treatment. 
  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. 
  • Alemtuzumab for the prevention and treatment of graft-versus-host disease. 
  • Alopecia associated with fluconazole therapy. 
  • Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day. 
  • Alternating ibuprofen and acetaminophen in the treatment of febrile children: a pilot study [ISRCTN30487061]. 
  • Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. 
  • Amifostine as a radioprotectant. 
  • Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. 
  • Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. 
  • Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization. 
  • Antepartum or postpartum isoniazid treatment of latent tuberculosis infection. 
  • Antiandrogens in the treatment of priapism. 
  • Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. 
  • Antibiotic use and misuse in the neonatal intensive care unit. 
  • Anticoagulation in heart failure: current status and future direction. 
  • Antidepressant-like effects of nicotine and reduced nicotinic receptor binding in the Fawn-Hooded rat, an animal model of co-morbid depression and alcoholism. 
  • Antiemetics: American Society of Clinical Oncology clinical practice guideline update. 
  • Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. 
  • Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV. 
  • Antiretroviral treatment strategies in resource-limited settings. 
  • Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). 
  • Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. 
  • Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. 
  • Applying the new STEMI guidelines: 1. Reperfusion in acute ST-segment elevation myocardial infarction. 
  • Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. 
  • Aprotinin's effect on blood product transfusion in off-pump bilateral lung transplantation. 
  • Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. 
  • Are Prophylactic Postoperative Antibiotics Necessary for Immediate Breast Reconstruction? Results of a Prospective Randomized Clinical Trial. 
  • Aspirin dose and six-month outcome after an acute coronary syndrome. 
  • Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. 
  • Assessment and management of donor pain following marrow harvest for allogeneic bone marrow transplantation. 
  • Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Association between timing of zoledronic acid infusion and hip fracture healing. 
  • Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. 
  • Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. 
  • Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. 
  • Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. 
  • Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. 
  • BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors. 
  • Bacterial temporal dynamics enable optimal design of antibiotic treatment. 
  • Balancing the cyclooxygenase portfolio. 
  • Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. 
  • Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. 
  • Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). 
  • Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. 
  • Bevacizumab and daily temozolomide for recurrent glioblastoma. 
  • Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. 
  • Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. 
  • Bidirectional interaction of valproate and lamotrigine in healthy subjects. 
  • Biologic activity of tamoxifen at low doses in healthy women. 
  • Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia. 
  • Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. 
  • Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. 
  • Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. 
  • Bowel preparation before colonoscopy. 
  • Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. 
  • Bupropion SR in the naturalistic treatment of elderly patients with major depression. 
  • Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. 
  • Bupropion sustained release: a therapeutic overview. 
  • C1q acts synergistically with phorbol dibutyrate to activate CR1-mediated phagocytosis by human mononuclear phagocytes. 
  • COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat. 
  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. 
  • Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? 
  • Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. 
  • Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis. 
  • Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93). 
  • Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. 
  • Caspofungin for invasive candidiasis at a tertiary care medical center. 
  • Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. 
  • Cellular pharmacokinetic and pharmacodynamic analyses of ethacrynic acid: Implications in topical drug delivery in the eye. 
  • Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. 
  • Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. 
  • Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. 
  • Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature. 
  • Chlorpyrifos targets developing glia: effects on glial fibrillary acidic protein. 
  • Cholinergic therapy for Down's syndrome. 
  • Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. 
  • Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. 
  • Chorioamnionitis: is continuation of antibiotic therapy necessary after cesarean section? 
  • Chronic administration of U50,488H fails to produce hypothalamo-pituitary-adrenal axis tolerance in neonatal rats. 
  • Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. 
  • Chronic nicotine and dizocilpine effects on regionally specific nicotinic and NMDA glutamate receptor binding. 
  • Chronic nicotine interactions with clozapine and risperidone and attentional function in rats. 
  • Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. 
  • Chronic treatment with haloperidol induces deficits in working memory and feedback effects of interval timing. 
  • Chronic very low dose naltrexone administration attenuates opioid withdrawal expression. 
  • Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease. 
  • Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates. 
  • Clinical Decisions. Treatment of mild persistent asthma. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. 
  • Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. 
  • Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. 
  • Clinical experience with substance P receptor (NK1) antagonists in depression. 
  • Clinical inquiries. How effective are hypertension self-care interventions? 
  • Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). 
  • Clinical outcomes among stroke patients receiving tissue plasminogen activator therapy beyond the 3-hour time window. 
  • Clinical outcomes of bivalirudin for ischemic heart disease. 
  • Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. 
  • Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). 
  • Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. 
  • Clinical variables associated with early administration of antipsychotics in bipolar mania. 
  • Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. 
  • Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. 
  • Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. 
  • Clozapine-, but not haloperidol-, induced increases in deltaFosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors. 
  • Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. 
  • Colistin: still a lifesaver for the 21st century? 
  • Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). 
  • Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus. 
  • Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1). 
  • Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. 
  • Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. 
  • Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. 
  • Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. 
  • Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. 
  • Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. 
  • Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. 
  • Complement factor 1 inhibitor improves cardiopulmonary function in neonatal cardiopulmonary bypass. 
  • Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. 
  • Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. 
  • Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. 
  • Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. 
  • Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. 
  • Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. 
  • Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. 
  • Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. 
  • Conversations in cardiology: bridging antiplatelet therapy before surgery. 
  • Converting i.v. nitroglycerin therapy to nitroglycerin ointment therapy: a comparison of two methods. 
  • Correlates of intake of folic acid-containing supplements among pregnant women. 
  • Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study. 
  • Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. 
  • Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. 
  • Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. 
  • Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). 
  • Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. 
  • Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. 
  • Cryoprecipitate therapy. 
  • Cyclophosphamide, cisplatin, and carmustine: pharmacokinetics of carmustine following multiple alkylating-agent interactions. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. 
  • DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. 
  • DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. 
  • Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. 
  • Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. 
  • Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. 
  • Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. 
  • Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. 
  • Delayed administration of recombinant human parathyroid hormone improves early biomechanical strength in a rat rotator cuff repair model. 
  • Delaying the initiation of progesterone supplementation results in decreased pregnancy rates after in vitro fertilization: a randomized, prospective study. 
  • Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy. 
  • Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. 
  • Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator. 
  • Determining contrast medium dose and rate on basis of lean body weight: does this strategy improve patient-to-patient uniformity of hepatic enhancement during multi-detector row CT? 
  • Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid. 
  • Diagnosis and Management of VTE in Pregnancy. 
  • Diagnosis and management of group B streptococcus in pregnancy. 
  • Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone. 
  • Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. 
  • Discontinuation of clonazepam in the treatment of social phobia. 
  • Disposition, elimination, and metabolism of tri-o-cresyl phosphate following daily oral administration in Fischer 344 male rats. 
  • Diuretic strategies in patients with acute decompensated heart failure. 
  • Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. 
  • Does Extended Pre Quit Bupropion Aid in Extinguishing Smoking Behavior? 
  • Does antidepressant therapy improve cognition in elderly depressed patients? 
  • Dofetilide dose reductions and discontinuations in women compared with men. 
  • Donepezil for Down's syndrome. 
  • Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial. 
  • Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. 
  • Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. 
  • Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory study. 
  • Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). 
  • Dosing recommendations and prescribing patterns for depressed medically ill hospitalized older patients. 
  • Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension. 
  • Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. 
  • Duration of empirical antibiotic therapy for infants suspected of early-onset sepsis. 
  • Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α. 
  • Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome). 
  • Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group. 
  • Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. 
  • Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. 
  • Early propranolol treatment induces lung heme-oxygenase-1, attenuates metabolic dysfunction, and improves survival following experimental sepsis. 
  • Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care. 
  • Early versus delayed, provisional eptifibatide in acute coronary syndromes. 
  • Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. 
  • Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial. 
  • Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial. 
  • Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. 
  • Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. 
  • Effect of bar-code technology on the safety of medication administration. 
  • Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. 
  • Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. 
  • Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. 
  • Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. 
  • Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. 
  • Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study. 
  • Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. 
  • Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. 
  • Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. 
  • Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST). 
  • Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. 
  • Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). 
  • Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. 
  • Effect of varying injection rates of a saline chaser on aortic enhancement in CT angiography: phantom study. 
  • Effectiveness of a gentamicin dosing protocol based on postconceptional age: comparison to published neonatal guidelines. 
  • Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients. 
  • Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. 
  • Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. 
  • Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. 
  • Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. 
  • Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. 
  • Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. 
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. 
  • Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. 
  • Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. 
  • Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. 
  • Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. 
  • Effects of magnesium sulfate in kainic acid-induced status epilepticus. 
  • Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. 
  • Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. 
  • Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. 
  • Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. 
  • Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study. 
  • Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. 
  • Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. 
  • Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). 
  • Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. 
  • Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism. 
  • Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. 
  • Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. 
  • Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. 
  • Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). 
  • Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). 
  • Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. 
  • Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. 
  • Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. 
  • Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. 
  • Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. 
  • Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study. 
  • Efficacy of gabapentin therapy in children with refractory partial seizures. 
  • Efficacy of multiple intraarterial papaverine infusions for improvement in cerebral circulation time in patients with recurrent cerebral vasospasm. 
  • Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. 
  • Efficacy of remission-induction regimens for ANCA-associated vasculitis. 
  • Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. 
  • Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. 
  • Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. 
  • Electromyographic, neuropathologic, and functional correlates in the cat as the result of tri-o-cresyl phosphate delayed neurotoxicity. 
  • Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. 
  • Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction. 
  • End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. 
  • Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. 
  • Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome. 
  • Enhanced behavioral response to repeated-dose cocaine in adolescent rats. 
  • Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. 
  • Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation. 
  • Epidermal growth factor augments adaptation following small bowel resection: optimal dosage, route, and timing of administration. 
  • Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. 
  • Epinephrine for cardiac arrest: are we doing more harm than good? 
  • Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. 
  • Escitalopram in specific phobia: results of a placebo-controlled pilot trial. 
  • Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. 
  • Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials. 
  • European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. 
  • Evaluating the impact of public health notification: Duke clopidogrel experience. 
  • Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. 
  • Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. 
  • Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. 
  • Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. 
  • Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. 
  • Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. 
  • Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. 
  • Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. 
  • Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. 
  • Extending principles learned in model systems to clinical trials design. 
  • External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models. 
  • Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia. 
  • Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. 
  • Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. 
  • Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. 
  • Final report of the Lyme disease review panel of the Infectious Diseases Society of America. 
  • First-line pharmacotherapy approaches for generalized anxiety disorder. 
  • Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. 
  • Fluconazole prophylaxis for prevention of invasive candidiasis in infants. 
  • Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial. 
  • Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. 
  • Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. 
  • Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. 
  • Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. 
  • Functional status in depressed patients: the relationship to disease severity and disease resolution. 
  • Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. 
  • Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support. 
  • GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents? 
  • Gaps in Drug Dosing for Obese Children: A Systematic Review of Commonly Prescribed Emergency Care Medications. 
  • Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. 
  • Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection. 
  • Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. 
  • Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. 
  • Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin. 
  • Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. 
  • Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. 
  • Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. 
  • Health-related quality of life after tricompartment knee arthroplasty with and without an extended-duration continuous femoral nerve block: a prospective, 1-year follow-up of a randomized, triple-masked, placebo-controlled study. 
  • Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial. 
  • High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. 
  • High dose chemotherapy with autologous peripheral blood progenitor cell transplantation in an anephric child with multiply recurrent Wilms tumor. 
  • High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. 
  • High dose factor VIIa improves clot structure and stability in a model of haemophilia B. 
  • High dose intravenous immunoglobulin does not affect complement-bacteria interactions. 
  • High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study. 
  • High-dose cisplatin in disseminated melanoma: a comparison of two schedules. 
  • High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. 
  • High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. 
  • High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. 
  • High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. 
  • High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. 
  • High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. 
  • High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). 
  • Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. 
  • Histamine H(1) antagonist treatment with pyrilamine reduces nicotine self-administration in rats. 
  • Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. 
  • Hormonal consequences of "missing the pill". 
  • Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. 
  • Hormonal treatment of an endometrial stromal nodule followed by local excision. 
  • Hospital ward antibiotic prescribing and the risks of Clostridium difficile infection. 
  • Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. 
  • Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. 
  • IL-12/GM-CSF coadministration in an SIV DNA prime/protein boost protocol enhances Gag-specific T cells but not virus-specific neutralizing antibodies in rhesus macaques. 
  • Ifosfamide enantiomers: pharmacokinetics in children. 
  • Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. 
  • Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. 
  • Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. 
  • Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. 
  • Impact of an Alcohol Withdrawal Treatment Pathway on Hospital Length of Stay: A Retrospective Observational Study Comparing Pre and Post Pathway Implementation. 
  • Impact of chemotherapy dose intensity on cancer patient outcomes. 
  • Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. 
  • Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. 
  • Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. 
  • Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. 
  • Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. 
  • In-hospital management of type 2 diabetes mellitus. 
  • Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. 
  • Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. 
  • Induction of tyrosine hydroxylase in the locus coeruleus of transgenic mice in response to stress or nicotine treatment: lack of activation of tyrosine hydroxylase promoter activity. 
  • Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. 
  • Inflammatory breast carcinoma. Effective multimodal approach. 
  • Infliximab in active early rheumatoid arthritis. 
  • Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Informing the dosing of interventions in randomized trials. 
  • Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. 
  • Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. 
  • Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. 
  • Inhibition of premature labor: a multicenter comparison of ritodrine and ethanol. 
  • Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. 
  • Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma. 
  • Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. 
  • Interferon in the treatment of cutaneous T-cell lymphoma. 
  • Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment. 
  • Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. 
  • Intermittent preventive malaria treatment in Tanzanian infants. 
  • Intermittent preventive treatment for malaria in infants: moving forward, cautiously. 
  • Intracerebral hemorrhage after pipeline embolization: Management of antiplatelet agents and the case for point-of-care testing--case reports and review of literature. 
  • Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study. 
  • Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. 
  • Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. 
  • Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. 
  • Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. 
  • Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. 
  • Is weekly iron and folic acid supplementation as effective as daily supplementation for decreasing incidence of anemia in adolescent girls? 
  • Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats. 
  • Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center. 
  • Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. 
  • Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. 
  • Late administration of Mn porphyrin-based SOD mimic enhances diabetic complications. 
  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. 
  • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. 
  • Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. 
  • Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. 
  • Levothyroxine improves subjective sleepiness in a euthyroid patient with narcolepsy without cataplexy. 
  • Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. 
  • Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. 
  • Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. 
  • Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. 
  • Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes. 
  • Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. 
  • Long-term follow-up of men with male pattern baldness treated with topical minoxidil. 
  • Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. 
  • Long-term neuroprotection from a potent redox-modulating metalloporphyrin in the rat. 
  • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. 
  • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. 
  • Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. 
  • Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. 
  • Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. 
  • Long-term tolerability and efficacy of lamotrigine in infants 1 to 24 months old. 
  • Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. 
  • Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. 
  • Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. 
  • Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. 
  • Luteal supplementation in in vitro fertilization: more questions than answers. 
  • Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen. 
  • Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. 
  • Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). 
  • Management of childhood onset nephrotic syndrome. 
  • Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. 
  • Management of invasive mycoses in hematology patients: current approaches. 
  • Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. 
  • Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. 
  • Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. 
  • Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. 
  • Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. 
  • Measuring the effect of inappropriate initial antibiotic therapy on outcomes of patients with Gram-negative sepsis: An imprecise science. 
  • Medical management of adrenal cortical disease. 
  • Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. 
  • Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. 
  • Menopausal hormones and risk of ovarian cancer. 
  • Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. 
  • Methylprednisolone reduces the inflammatory response to cardiopulmonary bypass in neonatal piglets: timing of dose is important. 
  • Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. 
  • Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited. 
  • Mind the Gap: Gaps in Antidepressant Treatment, Treatment Adjustments, and Outcomes among Patients in Routine HIV Care in a Multisite U.S. Clinical Cohort. 
  • Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. 
  • Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). 
  • Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. 
  • Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 
  • Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. 
  • Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease. 
  • Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. 
  • Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. 
  • Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. 
  • Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. 
  • Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. III. Histopathology. 
  • Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report. 
  • Mycobacteria: treatment approaches and mechanisms of resistance. 
  • Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. 
  • Myeloid growth factors. 
  • Nasal toxicity of manganese sulfate and manganese phosphate in young male rats following subchronic (13-week) inhalation exposure. 
  • National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain. 
  • Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. 
  • Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. 
  • Neonatal dexamethasone treatment leads to alterations in cell signaling cascades controlling hepatic and cardiac function in adulthood. 
  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. 
  • Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant. 
  • New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. 
  • New therapies for chronic hepatitis C virus infection. 
  • New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. 
  • Nicotine for postoperative analgesia: a systematic review and meta-analysis. 
  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. 
  • Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. 
  • Nonsteroidal anti-inflammatory drugs and acetaminophen in the treatment of an acute muscle injury. 
  • Not ready for prime time. 
  • Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. 
  • Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 
  • Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. 
  • Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. 
  • Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. 
  • Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes. 
  • Once-daily aminoglycoside dosing. 
  • Once-daily aminoglycoside dosing. 
  • Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. 
  • Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis. 
  • Once-yearly zoledronic acid in older men compared with women with recent hip fracture. 
  • One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. 
  • Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. 
  • Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. 
  • Open trial of nefazodone for combat-related posttraumatic stress disorder. 
  • Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. 
  • Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. 
  • Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. 
  • Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. 
  • Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. 
  • Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. 
  • Oral bisphosphonate compliance and persistence: a matter of choice? 
  • Oral cleft prevention program (OCPP). 
  • Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group. 
  • Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. 
  • Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. 
  • Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. 
  • Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). 
  • Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. 
  • Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. 
  • Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. 
  • Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. 
  • Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study. 
  • PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. 
  • Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience. 
  • Parameters for lithium treatment are critical in its enhancement of fracture-healing in rodents. 
  • Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. 
  • Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. 
  • Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors. 
  • Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. 
  • Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation. 
  • Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. 
  • Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). 
  • Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. 
  • Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. 
  • Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. 
  • Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke. 
  • Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. 
  • Perioperative methylprednisolone and outcome in neonates undergoing heart surgery. 
  • Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. 
  • Peripheral vascular complications during transcatheter aortic valve replacement: management and potential role of chronic steroid use. 
  • Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. 
  • Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. 
  • Persistent cardiovascular effects with repeated caffeine administration. 
  • Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. 
  • Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. 
  • Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study. 
  • Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. 
  • Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. 
  • Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature. 
  • Pharmacokinetics and tolerance of zidovudine in preterm infants. 
  • Pharmacokinetics of Clindamycin in Obese and Nonobese Children. 
  • Pharmacokinetics of levetiracetam. 
  • Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. 
  • Pharmacokinetics of rifampicin. 
  • Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. 
  • Pharmacologic treatment of acute and chronic stress following trauma: 2006. 
  • Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. 
  • Pharmacotherapy of bipolar disorder in old age: review and recommendations. 
  • Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. 
  • Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. 
  • Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. 
  • Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. 
  • Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. 
  • Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. 
  • Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. 
  • Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. 
  • Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. 
  • Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. 
  • Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. 
  • Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. 
  • Phase I studies with the novel nucleoside analog gemcitabine. 
  • Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. 
  • Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies. 
  • Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer. 
  • Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. 
  • Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. 
  • Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. 
  • Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. 
  • Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. 
  • Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. 
  • Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. 
  • Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. 
  • Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. 
  • Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832). 
  • Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. 
  • Phase I trial of pazopanib in patients with advanced cancer. 
  • Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. 
  • Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. 
  • Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. 
  • Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. 
  • Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. 
  • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. 
  • Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. 
  • Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. 
  • Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. 
  • Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. 
  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. 
  • Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. 
  • Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer. 
  • Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. 
  • Phase II study of carboplatin in children with progressive low-grade gliomas. 
  • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. 
  • Phase II study of docetaxel in advanced soft tissue sarcomas. 
  • Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. 
  • Phase II study of gemcitabine in advanced colorectal adenocarcinoma. 
  • Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. 
  • Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. 
  • Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. 
  • Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. 
  • Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. 
  • Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. 
  • Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. 
  • Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. 
  • Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study. 
  • Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. 
  • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. 
  • Phase II trial of fazarabine in advanced colorectal carcinoma. 
  • Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. 
  • Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. 
  • Phase II trial of mitoguazone in children with leukemia and lymphoma: a Pediatric Oncology Group Study. 
  • Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. 
  • Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. 
  • Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. 
  • Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. 
  • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. 
  • Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. 
  • Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. 
  • Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. 
  • Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. 
  • Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor. 
  • Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. 
  • Plasma concentration time course and pharmacological effects of a standardized oral amiodarone dosing regimen in humans. 
  • Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? 
  • Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. 
  • Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. 
  • Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. 
  • Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. 
  • Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. 
  • Postoperative antibiotic therapy for children with perforated appendicitis: long course of intravenous antibiotics versus early conversion to an oral regimen. 
  • Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. The Pediatric Oncology Group. 
  • Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. 
  • Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. 
  • Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria. 
  • Potential opioid-sparing effect of regular benzodiazepines in dyspnea: longer duration of studies needed. 
  • Practical injection-rate CT perfusion imaging: deconvolution-derived hemodynamics in a case of stroke. 
  • Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial. 
  • Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. 
  • Precatheterization Use of P2Y12 Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry®. 
  • Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. 
  • Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. 
  • Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. 
  • Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. 
  • Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections. 
  • Pregabalin in generalized anxiety disorder: a placebo-controlled trial. 
  • Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. 
  • Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. 
  • Prenatal cocaine and cell development in rat brain regions: effects on ornithine decarboxylase and macromolecules. 
  • Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. 
  • Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. 
  • Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. 
  • Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 
  • Prevention of intrathecal baclofen withdrawal syndrome: successful use of a temporary intrathecal catheter. 
  • Prevention of recurrent postpartum depression: a randomized clinical trial. 
  • Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. 
  • Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. 
  • Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. 
  • Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. 
  • Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. 
  • Prolonged nicotine patch use in quitters with past abstinence-induced depressed mood. 
  • Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. 
  • Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). 
  • Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. 
  • Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. 
  • Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. 
  • Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. 
  • Psychotropic drug prescriptions for nursing home residents. 
  • Pulmonary and pleural responses in Fischer 344 rats following short-term inhalation of a synthetic vitreous fiber. I. Quantitation of lung and pleural fiber burdens. 
  • Pulmonary and pleural responses in Fischer 344 rats following short-term inhalation of a synthetic vitreous fiber. II. Pathobiologic responses. 
  • Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis. 
  • Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey. 
  • Quetiapine XR: current status for the treatment of major depressive disorder. 
  • RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. 
  • Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. 
  • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. 
  • Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. 
  • Randomized controlled trial of 3 vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis. 
  • Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. 
  • Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. 
  • Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. 
  • Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. 
  • Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. 
  • Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. 
  • Randomized, double-blind trial of cefonicid and nafcillin in the treatment of skin and skin structure infections. 
  • Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. 
  • Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury. 
  • Ranibizumab and bevacizumab for neovascular age-related macular degeneration. 
  • Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. 
  • Rate of resolution of histologically verified intracranial tuberculomas. 
  • Rational opioid dosing in the elderly: dose and dosing interval when initiating opioid therapy. 
  • Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. 
  • Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. 
  • Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. 
  • Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. 
  • Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. 
  • Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. 
  • Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. 
  • Recombinant activated factor VII and the anaesthetist. 
  • Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. 
  • Reducing long-term diazepam prescribing in office practice. A controlled trial of educational visits. 
  • Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. 
  • Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. 
  • Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. 
  • Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. 
  • Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). 
  • Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. 
  • Relationship between nociceptor activity, peripheral edema, spinal microglial activation and long-term hyperalgesia induced by formalin. 
  • Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. 
  • Relationship of carbamazepine reduction rate to seizure frequency during inpatient telemetry. 
  • Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. 
  • Remifentanil and intubating conditions. 
  • Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. 
  • Reply to abnormalities on the multifocal electroretinogram may precede clinical signs of hydroxychloroquine retinotoxicity. 
  • Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. 
  • Resolving postoperative neuroinflammation and cognitive decline. 
  • Respiratory Support for Very Low Birth Weight Infants Receiving Dexamethasone. 
  • Response of infantile spasms to levetiracetam. 
  • Response rate as an endpoint in clinical trials. 
  • Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. 
  • Results of a pilot trial comparing prolonged intravenous antibiotics with sequential intravenous/oral antibiotics for children with perforated appendicitis. 
  • Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. 
  • Results of recent large myocardial infarction trials, adjunctive therapies, and acute myocardial infarction: improving outcomes. 
  • Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine. 
  • Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. 
  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. 
  • Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. 
  • Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. 
  • Risk of cerebral vasopasm after subarachnoid hemorrhage reduced by statin therapy: A multivariate analysis of an institutional experience. 
  • Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 
  • Robust rat pulmonary radioprotection by a lipophilic Mn N-alkylpyridylporphyrin, MnTnHex-2-PyP(5+). 
  • Role of gonadotropin-releasing hormone pulse frequency in differential regulation of gonadotropins in the gilt. 
  • Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C. 
  • Role of mu-opioid and NMDA receptors in the development and maintenance of repeated swim stress-induced thermal hyperalgesia. 
  • Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes. 
  • Routine bivalirudin use in percutaneous carotid interventions. 
  • Safe and Efficacious Use of Automated Bolus Advisors in Individuals Treated With Multiple Daily Insulin Injection (MDI) Therapy: Lessons Learned From the Automated Bolus Advisor Control and Usability Study (ABACUS). 
  • Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. 
  • Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. 
  • Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). 
  • Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses: A Meta-Analysis. 
  • Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. 
  • Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. 
  • Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. 
  • Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. 
  • Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients. 
  • Safety and efficacy of weekly oral oltipraz in chronic smokers. 
  • Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis. 
  • Safety and pharmacokinetics of repeat-dose micafungin in young infants. 
  • Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. 
  • Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. 
  • Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. 
  • Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. 
  • Safety of quinacrine contraceptive pellets: results from 10-year follow-up in Vietnam. 
  • Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. 
  • Saline vs Tissue Plasminogen Activator Irrigations after Drain Placement for Appendicitis-Associated Abscess: A Prospective Randomized Trial. 
  • Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. 
  • Schedule-dependent enhanced lethality with combined administration of actinomycin D and tumor necrosis factor in mice. 
  • Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine. 
  • Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. 
  • Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE. 
  • Separate or sequential exposure to nicotine prenatally and in adulthood: persistent effects on acetylcholine systems in rat brain regions. 
  • Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. 
  • Sertraline in children and adolescents with social anxiety disorder: an open trial. 
  • Serum tocopherol levels in very preterm infants after a single dose of vitamin E at birth. 
  • Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. 
  • Short-term and long-term treatment for bipolar patients: beyond the guidelines. 
  • Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. 
  • Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. 
  • Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. 
  • Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. 
  • Single-dose amoxicillin therapy with follow-up urine culture. Effective initial management for acute uncomplicated urinary tract infections. 
  • Single-dose oritavancin in the treatment of acute bacterial skin infections. 
  • Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. 
  • Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. 
  • Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. 
  • Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. 
  • Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. 
  • Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. 
  • Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease. 
  • Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers. 
  • Stimulation of insulin secretion by a rapid intravenous calcium infusion in patients with beta-cell neoplasms of the pancreas. 
  • Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. 
  • Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. 
  • Subchronic dermal application of N,N-diethyl m-toluamide (DEET) and permethrin to adult rats, alone or in combination, causes diffuse neuronal cell death and cytoskeletal abnormalities in the cerebral cortex and the hippocampus, and Purkinje neuron loss in the cerebellum. 
  • Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. 
  • Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. 
  • Successful use of intravenous immunoglobulin as initial monotherapy in Landau-Kleffner syndrome. 
  • Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group. 
  • Sustained improvement in photodamaged skin with reduced tretinoin emollient cream treatment regimen: effect of once-weekly and three-times-weekly applications. 
  • Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. 
  • Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. 
  • TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. 
  • TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial. 
  • Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). 
  • Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. 
  • Telaprevir for the treatment of chronic hepatitis C infection. 
  • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. 
  • Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies. 
  • Temozolomide in children with progressive low-grade glioma. 
  • The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. 
  • The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. 
  • The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. 
  • The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. 
  • The distribution of cocaine in mice differs by age and strain. 
  • The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. 
  • The effects of age, exposure history and malaria infection on the susceptibility of Anopheles mosquitoes to low concentrations of pyrethroid. 
  • The efficacy of the appetite suppressant, diethylpropion, is dependent on both when it is given (day vs. night) and under conditions of high fat dietary restriction. 
  • The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. 
  • The impact of bispectral index monitoring on rates of propofol administration. 
  • The impact of patient compliance on drug concentration profile in multiple doses. 
  • The importance of chemotherapy dose intensity in lung cancer. 
  • The importance of dose in isocarboxazid therapy. 
  • The long-term treatment of panic disorder. 
  • The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea. 
  • The misuse and diversion of prescribed ADHD medications by college students. 
  • The pediatric preclinical testing program: description of models and early testing results. 
  • The rapid evolution of treatment strategies for hepatitis C. 
  • The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. 
  • The role of diazepam loading for the treatment of alcohol withdrawal syndrome in hospitalized patients. 
  • The spontaneous occurrence of paroxysmal supraventricular tachycardia. 
  • The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. 
  • The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. 
  • The use of once-daily dosing of gentamicin in obstetrics and gynecology. 
  • Therapy and clinical trials. 
  • Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. 
  • Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). 
  • Three months in the symptom life of a teenage girl undergoing treatment for cancer. 
  • Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. 
  • Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries. 
  • Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. 
  • Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. 
  • Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. 
  • Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. 
  • Too much of a good thing? Tracing the history of the propofol infusion syndrome. 
  • Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. 
  • Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. 
  • Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group. 
  • Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. 
  • Tranexamic Acid for Prevention and Treatment of Postpartum Hemorrhage: An Update on Management and Clinical Outcomes. 
  • Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. 
  • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. 
  • Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. 
  • Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. 
  • Treatment of established deep vein thrombosis: a review of the therapeutic armamentarium. 
  • Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. 
  • Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer. 
  • Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). 
  • Treatment of patients with pineoblastoma with high dose cyclophosphamide. 
  • Treatment of platelet alloimmunization with intravenous immunoglobulin. Two case reports and review of the literature. 
  • Treatment of posttraumatic stress disorder with nefazodone. 
  • Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. 
  • Treatment of psoriasis with piritrexim, a lipid-soluble folate antagonist. 
  • Treatment of pyoderma gangrenosum with cyclosporine. 
  • Treatment of tinnitus with gabapentin: a pilot study. 
  • Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. 
  • Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. 
  • Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. 
  • Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. 
  • Trends in Intravenous Antibiotic Duration for Urinary Tract Infections in Young Infants. 
  • Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants. 
  • Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. 
  • Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. 
  • Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. 
  • Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. 
  • Understanding operator stent choice in the catheterization laboratory using a pre-procedure survey: Opportunities for quality improvement. 
  • Understanding patient compliance and persistence with osteoporosis therapy. 
  • Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. 
  • Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Use of an automated bolus calculator reduces fear of hypoglycemia and improves confidence in dosage accuracy in patients with type 1 diabetes mellitus treated with multiple daily insulin injections. 
  • Use of an insulin bolus advisor facilitates earlier and more frequent changes in insulin therapy parameters in suboptimally controlled patients with diabetes treated with multiple daily insulin injection therapy: results of the ABACUS trial. 
  • Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients. 
  • Use of automated bolus advisors may improve adherence to multiple daily insulin injection therapy. 
  • Use of lamotrigine in a patient with a clozapine-related seizure. 
  • Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants. 
  • Use of newer antifungal therapies in clinical practice: what do the data tell us? 
  • Use of phenelzine in continuation therapy. 
  • Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. 
  • Use of very low-dose naltrexone during opiate detoxification. 
  • Uses of epoetin for anemia in oncology. 
  • Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences? 
  • Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. 
  • Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. 
  • Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial. 
  • Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. 
  • Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. 
  • Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor. 
  • Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. 
  • Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. 
  • Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. 
  • Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. 
  • Weaning of immunosuppression in liver transplant recipients. 
  • Weekly administration of cis-dichlorodiammineplatinum(II) in childhood solid tumors: a Southwest Oncology Group study. 
  • Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. 
  • Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. 
  • Weekly mitoxantrone therapy for refractory multiple myeloma: a Southeastern Cancer Study Group Trial. 
  • Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. 
  • Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. 
  • Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. 
  • Weight loss in narcolepsy patients treated with sodium oxybate. 
  • What CATIE found: results from the schizophrenia trial. 
  • Zinc and Vitamin Supplementation in an Under-5 Indigenous Population of Guatemala: Influence of Lay Health Promoters in Decreasing Incidence of Diarrhea. 
  • Zoledronic acid and clinical fractures and mortality after hip fracture. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Allen, Nancy Bates, Professor of Medicine, Medicine, Rheumatology and Immunology
  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Fekrat, Sharon, Professor of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Moorman, Patricia Gripka, Professor in Community and Family Medicine, Duke Cancer Institute
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Olson, Steven Arthur, Professor of Orthopaedic Surgery, Orthopaedics
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Warner, David Samuel, Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology
  • Zafar, Syed Yousuf, Associate Professor of Medicine, Medicine, Medical Oncology